Radioactive drug [225Ac]Ac-AKY-2519 for metastatic castration-resistant prostate cancer
Tests a radioactive drug in adults with prostate cancer that has spread.
Key facts
- Who runs it
- Aktis Oncology, Inc.
- Where
- Boston, Grand Rapids, Irvine, Kansas City, Metairie, Miami, Omaha, and Pittsburgh, United StatesSee the 8 sites
- Trial code
- Registry title
- A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 138 people, planned
- Started
- 17 Jun 2026
- Expected to end
- Jun 2032
- Type of study
- Interventional
- Treatments tested
- [225Ac]Ac-AKY-2519 (therapeutic)
- [64Cu]Cu-AKY-2519 (imaging)
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. It tests a radioactive drug, [225Ac]Ac-AKY-2519.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma confirmed by tissue or cell tests, with castrate testosterone levels (< 50 ng/dL) and documented progression on the most recent treatment, by PSA or imaging. ECOG performance status 0 or 1.
- Earlier treatment
- Cohort B needs 2 or more prior doses of 177Lu-PSMA-617 (PLUVICTO). Other people cannot have had targeted radiotherapy, a B7-H3 targeted therapy, more than 2 ARPIs or more than 1 taxane-based therapy in the mCRPC setting.
Main reasons for not taking part
- Prior treatment with a targeted radiotherapy (except 177Lu-PSMA-617 in Cohort B)
- Prior treatment with a B7-H3 targeted therapy
- More than 2 ARPIs and/or more than 1 taxane-based therapy in the mCRPC setting
- An investigational agent within the previous 28 days
- Impaired cardiac function or clinically significant cardiac disease
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age ≥ 18 years
- Histologic or cytologic confirmation of prostatic adenocarcinoma
- ECOG Performance Status of 0 or 1
- Adequate end-organ function
- Ability to give informed consent and comply with study requirements
- Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids
- Castrate levels of serum testosterone (< 50 ng/dL)
- Documented disease progression on most recent prior line of therapy, either by PSA or imaging-based progression
- Cohort B: Received 2 or more prior doses of 177Lu-PSMA-617 (PLUVICTO)
Who cannot take part
- Prior treatment with more than 2 Androgen receptor pathway inhibitors (ARPIs) and/or more than 1 taxane-based therapy in the mCRPC setting
- Prior treatment with a targeted radiotherapy; o Exception: Cohort B is required to have had at least 2 prior doses of 177Lu-PSMA-617 (PLUVICTO)
- Prior treatment with a B7-H3 targeted therapy
- Received an investigational agent within the previous 28 days
- Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity
- Impaired cardiac function or clinically significant cardiac disease
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesContact: Praful RaviTaking people
- BAMF HealthGrand Rapids, United StatesContact: Study CoordinatorTaking people
- Hoag Memorial Hospital PresbyterianIrvine, United StatesContact: Gary UlanerTaking people
- University of Kansas Medical CenterKansas City, United StatesContact: Study CoordinatorTaking people
- East Jefferson General Hospital - LCMC HealthMetairie, United StatesContact: Study CoordinatorTaking people
- Biogenix Molecular, LLCMiami, United StatesContact: Study CoordinatorTaking people
- XCancerOmaha, United StatesContact: Tony RomeroTaking people
- UPMCPittsburgh, United StatesContact: Ravi Patel, MDTaking people
About the trial
What the trial wants to find out
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).
The group in the trial
- [225Ac]Ac-AKY-2519Treatment being tested
Treatment: [225Ac]Ac-AKY-2519 (therapeutic) and [64Cu]Cu-AKY-2519 (imaging)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer
- Plain-language title
- Radioactive drug [225Ac]Ac-AKY-2519 for metastatic castration-resistant prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 November 2026